Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Post-Mkt 03-03 19:13:26 EST

1.16

+0.01

+0.87%

盘后1.15

-0.01-0.86%

19:09 EST

High1.20	Low1.11	Vol157.59K
Open1.13	D1 Closing1.15	Amplitude7.83%
Mkt Cap3.29M	Tradable Cap2.30M	Total Shares2.84M
T/O181.05K	T/O Rate7.94%	Tradable Shares1.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":1.16,"timestamp":1772571600000,"preClose":1.15,"halted":0,"volume":157586,"hourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.16,"latestTime":"19:09 EST","volume":1067,"amount":1223.218403,"timestamp":1772582940699,"change":-0.01,"changeRate":-0.008621,"amplitude":0.025862},"delay":0,"changeRate":0.008695652173913052,"floatShares":1984338,"shares":2835300,"eps":-12.129513,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"03-03 19:13:26 EST","open":1.13,"high":1.2,"low":1.11,"amount":181047.02547360002,"amplitude":0.078261,"askPrice":1.25,"askSize":7,"bidPrice":1.14,"bidSize":16,"shortable":3,"etf":0,"ttmEps":-12.129513,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.15,"latestTime":"09:23 EST","volume":7352,"amount":8379.559632,"timestamp":1772547832318,"change":-0.03,"changeRate":-0.026087,"amplitude":0.039826},"postHourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.16,"latestTime":"19:09 EST","volume":1067,"amount":1223.218403,"timestamp":1772582940699,"change":-0.01,"changeRate":-0.008621,"amplitude":0.025862},"volumeRatio":0.87115},"requestUrl":"/m/hq/s/DRMA/tweets","defaultTab":"tweets","newsList":[{"id":"2614405621","title":"Dermata Therapeutics Director Mary Fisher Resigns Effective March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405621?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:14","pubTimestamp":1772054076,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. said director Mary Fisher will resign from its board and all committee roles effective March 31, 2026. The company said her departure is not due to any disagreement and is related to her employer’s recent acquisition, which no longer allows her to serve on the board. The board will be reduced to seven members from eight.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLfzD1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2605044876","title":"Dermata Therapeutics files to sell 1.48M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2605044876","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605044876?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:05","pubTimestamp":1769119525,"startTime":"0","endTime":"0","summary":"17:03 EST Dermata Therapeutics (DRMA) files to sell 1.48M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","DRMA","BK4539"],"gpt_icon":0},{"id":"2604115862","title":"Dermata Therapeutics Granted Australian Patent for Spongilla-Based Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115862","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115862?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:07","pubTimestamp":1768914462,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced that the Australian Patent Office has granted its patent for a Spongilla technology combination as a method for treating acne. The patent, titled \"Compositions and methods for the treatment of skin conditions\" , follows a previously issued U.S. patent for the same technology. This development further strengthens Dermata's international intellectual property portfolio for its acne treatment innovations as the company prepares for the future launch of its once-weekly, over-the-counter acne treatment system. Additional patent applications are pending in other key markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8PSjS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRMA","BK4007","BK4539"],"gpt_icon":0},{"id":"2595758487","title":"Dermata Therapeutics Announces $12.4 Million Private Placement With Warrants and Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758487","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758487?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:06","pubTimestamp":1767042396,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced it has entered into definitive agreements for a private placement involving the issuance and sale of approximately 2,022,062 shares of common stock , along with series C and short-term series D warrants to purchase up to 2,022,062 shares each. The securities are being offered at a purchase price of $2.04 per share or pre-funded warrant, with total gross proceeds expected to be about $4.1 million upfront and up to an additional $8.3 million if all warrants are exercised. The exercise of both series C and D warrants is contingent upon stockholder approval and will have an exercise price of $2.04 per share. Dermata intends to use the proceeds for general corporate purposes, including product launch activities, research, and potential acquisitions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLb9RRY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","DRMA","BK4539"],"gpt_icon":0},{"id":"2594218642","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2594218642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594218642?lang=en_us&edition=fundamental","pubTime":"2025-12-27 03:31","pubTimestamp":1766777508,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics  said Wednesday it agreed to sell 2.02 million shares, along with related Series C and short-term Series D warrants, in a private placement priced at $2.04 a share, with gross proceeds of as much as $12.4 million.The stock fell 20% as intraday volume topped 617,800 shares, compared with the daily average of 537,661.Aptevo Therapeutics  will implement a 1-for-18 reverse stock split, effective at the start of trading on Tuesday.The shares fell 38% as intraday volume topped 13.6 million, compared with the daily average of 2.09 million.Price: 1.91, Change: -0.47, Percent Change: -19.62","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APVO","BK4007","DRMA","BK4539","BK4139"],"gpt_icon":0},{"id":"2594405411","title":"Why Is Dermata Therapeutics Stock Surging Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405411","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594405411?lang=en_us&edition=fundamental","pubTime":"2025-12-25 00:32","pubTimestamp":1766593920,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C warrants, and Series D warrants.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/24/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/24/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49585324/why-is-dermata-therapeutics-stock-surging-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49585324/why-is-dermata-therapeutics-stock-surging-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["DRMA","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2586602406","title":"Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586602406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586602406?lang=en_us&edition=fundamental","pubTime":"2025-11-26 04:25","pubTimestamp":1764102327,"startTime":"0","endTime":"0","summary":"Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics and keeping the price target at $10.00. Anthony Vendetti ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"gpt_icon":0},{"id":"2586090491","title":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2586090491","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586090491?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:13","pubTimestamp":1764008038,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million Nov 24  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILINGSource text: [ID:n0001493152-25-024720]Further company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","DRMA"],"gpt_icon":0},{"id":"2586499833","title":"Dermata Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586499833?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:35","pubTimestamp":1764002108,"startTime":"0","endTime":"0","summary":"11:34 EST Dermata Therapeutics (DRMA) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2584501939","title":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584501939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584501939?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:08","pubTimestamp":1763464096,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC FilingNov 18  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATEFurther company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4007","BK4139"],"gpt_icon":0},{"id":"2584939345","title":"Dermata Therapeutics Inc - Termination Linked to Strategic Shift to Otc Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939345?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","DRMA","BK4007","BK4139"],"gpt_icon":0},{"id":"2584939312","title":"Dermata Therapeutics : Villani Will Not Be Entitled to Receive Any Further Milestones or Other Payments Due After Termination Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939312?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DRMA","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2584802939","title":"Dermata Therapeutics Inc - on Nov 17, Terminates License Agreement With Villani Dated March 31, 2017 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584802939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584802939?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DRMA","BK4539","BK4139"],"gpt_icon":0},{"id":"2583684986","title":"BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684986?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:20","pubTimestamp":1763155231,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC FilingNov 14  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ANNOUNCES STRATEGIC PIVOT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS INC - TO LAUNCH FIRST OTC ACNE KIT MID-2026 - SEC FILINGSource text: [ID:n0001493152-25-023419]Further company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2583868418","title":"Dermata Therapeutics Q3 net loss narrows as R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868418","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583868418?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:20","pubTimestamp":1763155226,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Q3 net loss narrows as R&D expenses fallOverviewDermata reports Q3 net loss of $1.7 mln, with decreased R&D expensesCompany shifts focus to OTC dermatology products, plans 2026 pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ13P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRMA","BK4007","BK4539"],"gpt_icon":0},{"id":"2583684514","title":"Dermata Therapeutics Inc - to Launch First Otc Acne Kit Mid-2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684514?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:18","pubTimestamp":1763155112,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DRMA","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2583545684","title":"Dermata Therapeutics Inc - Announces Strategic Pivot to Otc Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583545684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583545684?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:18","pubTimestamp":1763155112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DRMA","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2583848586","title":"Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2583848586","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583848586?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:10","pubTimestamp":1763154630,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology. Dermata Therapeutics Inc. has announced a strategic shift from developing prescription dermatology products to focusing on over-the-counter  dermatology treatments. The company plans to launch its first OTC product, a once-weekly acne kit utilizing its Spongilla technology, in mid-2026. Preparations are underway for branding, packaging, and manufacturing of this product. Dermata intends to market the acne kit directly to consumers, estheticians, and dermatologists for in-office treatments. The company aims to build a scalable portfolio of products that combine medical-grade science with everyday convenience, targeting a broader consumer base through accessible, effective dermatologic solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL82BDk7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2583681083","title":"Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681083","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681083?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:07","pubTimestamp":1763154446,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48879885/dermata-therapeutics-q3-eps-1-65-misses-1-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"gpt_icon":0},{"id":"2581831008","title":"Dermata Therapeutics Increases Stock Offering by $1.79M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831008","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831008?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:38","pubTimestamp":1762551535,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) just unveiled an update. On November 7, 2025, Dermata Therapeutics announced an increase in the maximum aggregate ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-increases-stock-offering-by-1-79m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-increases-stock-offering-by-1-79m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DRMA","BK4007","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com","stockEarnings":[{"period":"1week","weight":-0.1016},{"period":"1month","weight":-0.4889},{"period":"3month","weight":-0.6154},{"period":"6month","weight":-0.805},{"period":"1year","weight":-0.8991},{"period":"ytd","weight":-0.5043}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.070436},{"month":2,"riseRate":0,"avgChangeRate":-0.221628},{"month":3,"riseRate":0.2,"avgChangeRate":-0.174591},{"month":4,"riseRate":0.25,"avgChangeRate":-0.08308},{"month":5,"riseRate":0,"avgChangeRate":-0.156549},{"month":6,"riseRate":0.25,"avgChangeRate":-0.174977},{"month":7,"riseRate":0.25,"avgChangeRate":-0.133285},{"month":8,"riseRate":0.25,"avgChangeRate":-0.03319},{"month":9,"riseRate":0,"avgChangeRate":-0.128292},{"month":10,"riseRate":0.4,"avgChangeRate":-0.136086},{"month":11,"riseRate":0.2,"avgChangeRate":-0.072999},{"month":12,"riseRate":0.2,"avgChangeRate":-0.194478}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction